公开(公告)号：US20230234948A1

公开(公告)日：2023-07-27

申请号：US18009682

申请日：2021-06-10

Applicant: AMGEN INC.

Inventor： BENJAMIN C. MILGRAM ,  ISSAC E. MARX ,  JOHN STELLWAGEN ,  WEI ZHAO ,  ALAN H. CHERNEY

IPC: C07D413/12 ,  C07D401/12 ,  C07D417/12 ,  A61P29/00

CPC classification number: C07D413/12 ,  C07D401/12 ,  C07D417/12 ,  A61P29/00

Abstract: The present invention provides a compound of Formula (I): (I); an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular NaV1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

公开(公告)号：US20230227442A1

公开(公告)日：2023-07-20

申请号：US18009689

申请日：2021-06-11

Applicant: AMGEN INC.

Inventor： BENJAMIN C. MILGRAM ,  GWENAELLA RESCOURIO

IPC: C07D413/12 ,  C07D401/12 ,  A61P29/00

CPC classification number: C07D413/12 ,  C07D401/12 ,  A61P29/00

Abstract: The present invention provides heteroalkyl dihydroquinoline sulfonamide compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

公开(公告)号：US20210387977A1

公开(公告)日：2021-12-16

申请号：US17344939

申请日：2021-06-10

Applicant: AMGEN INC.

Inventor： BENJAMIN C. MILGRAM ,  Isaac E. MARX ,  John STELLWAGEN ,  Wei ZHAO ,  Alan H. CHERNEY

IPC: C07D413/12

Abstract: The present invention provides a compound of Formula (I): an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular NaV1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.